Johnson & Johnson to Buy Dutch Vaccine Group

Sept. 17, 2010
Value of acquisition is $2.3 billion

Cosmetics and pharmaceutical giant Johnson & Johnson said on Sept. 17 that it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about $2.3 billion.

"The companies expect that Crucell's strength in the manufacture, discovery and commercialization of vaccines would create a strong platform for Johnson & Johnson in the vaccine market," the two firms sai.

Johnson & Johnson already owns 17.5% of Crucell.

Crucell's headquarters will remain in Leiden in the Netherlands and J&J will preserve jobs at the Dutch company, which employs 1,300 people.

Last year Crucell produced more than 115 million vaccine doses in more than 100 countries, with the most of the treatments going to developing countries.

Copyright Agence France-Presse, 2010

Popular Sponsored Recommendations

Global Supply Chain Readiness Report: The Pandemic and Beyond

Sept. 23, 2022
Jabil and IndustryWeek look into how manufacturers are responding to supply chain woes.

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

How Organizations Connect and Engage with Frontline Workers

June 14, 2023
Nearly 80% of the 2.7 billion workers across manufacturing, construction, healthcare, transportation, agriculture, hospitality, and education are frontline. Learn best practices...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!